

---

# Promises of Stem Cell Research and Therapeutics

Indumathi Somasundaram, Kanmani Anandan,  
and Dhanasekaran Marappagounder

---

## Introduction

Stem cells are smart cells of the body. It is the origin of life. As stated by the great pathologist Rudolf Virchow, “All cells come from cells.” Today it is proved with evidence that all cells come from stem cells. The stem cells are derived from embryo, fetal tissues, and adult organs. Explicitly, stem cells can generate daughter cells identical to their mother (self-renewal), and under certain physiologic or experimental condition, depending on the source, they can differentiate into any type of cells such as heart muscle cells, blood cells, or the insulin-producing cells of the pancreas (differentiated cells). As the plant leaves flourishes from the stem, the body nourishes from the stem cells resting in our body. A more complete description of a stem cell includes a consideration of replication capacity, clonality, and potency. Thus, stem cells are considered to be unique cells with special attributes. It is

these special attributes that offer the vast potential serving as a repair system of the body. Ever since the discovery of stem cells [1–5], scientists have dreamed of using them to repair damaged tissue or create new organs and has revolutionized the field of medicine.

This chapter will thus, introduce stem cells, the history of stem cell research and its promises in the field of regenerative medicine.

---

## Stem Cell Background

Aristotle deduced that the embryo was derived from the mother’s menstrual blood. The hypothesis that life did not arise spontaneously, but rather only from preexisting life (*omne vivum ex vivo*) was pronounced by Leydig in 1855. Virchow (1855) then extended this to postulate that all cells in an organism are derived from preexisting cells (*omnis cellula e cellula*), the fertilized egg. According to the principles derived from Leydig, Virchow, and Pasteur, life as we know it neither ends nor begins but is continuous. The adult human, for example, is only one stage in the cycle of human life (Fig. 1) [6].

Thus, during early embryonic development, each stem cell divides and gives rise to two daughter cells with the same potential, which is called symmetric division, whereas during normal tissue renewal in the adult, each stem/progenitor cell gives rise to one daughter cell that remains a stem/progenitor cell and one daughter cell that begins the process of determination


---

I. Somasundaram (✉)  
Department of Stem Cell and Regenerative Medicine,  
Centre for Interdisciplinary Research, D.Y. Patil  
University, Kolhapur, India  
e-mail: [indu.stemcell@gmail.com](mailto:indu.stemcell@gmail.com)

K. Anandan  
Technology Ed, Midlothian, VA 23112, USA  
e-mail: [Kanmani.a@gmail.com](mailto:Kanmani.a@gmail.com)

D. Marappagounder  
Stem Cell Banking & Research, Ree Laboratories  
Private Limited, Mumbai 400053, India  
e-mail: [dhanasekarbio@gmail.com](mailto:dhanasekarbio@gmail.com)

**Fig. 1** Cycle of life. The life of an individual begins with formation of a fetus. Totipotent cells in the developing fetus migrate to the genital ridge and in adults produce germinal stem cells in the gonads. Germinal cells give rise to gametes (egg and sperm), resulting in cells containing half the chromosomes of an adult. Genetic reconstitution occurs when the sperm fertilizes the egg. Thus, life is continuous



to a terminally differentiated cell, which is called asymmetric division. The number of cells increases exponentially during early embryogenesis, but the cell number remains constant during normal tissue renewal, as the number of new stem/progenitor cells equals the number of cells destined to die.

## History of Stem Cells from the Scratch

The potential of stem cells to revolutionize medicine got a huge boost with the emergence of adult stem cells. This timeline takes us through the ups and downs of the stem cell rollercoaster. The history of stem cell research started in the beginning of 1800s with the discovery that some cells could generate other cells. In the early 1900s, the first real stem cells were discovered when it was found that some cells generate blood cells. Research into adult stem cells in animals and in humans has been ongoing since this time, and bone marrow transplants – actually a transplant of adult stem cells – have in fact been used in patients receiving radiations and chemotherapy since the 1950s [7].

In 1973, a team of physicians performed the first unrelated bone marrow transplant. It required seven transplants to be successful. The 1990s saw rapid expansion and success of the

National Marrow Donor Program (NMDP) with more than 38,000 transplants to date for the treatment of immunodeficiency and leukemia [8]. Developments in biotechnology in the 1980s and 1990s saw the introduction of first identity of embryonic stem cells and cloning by Martin Evans and Ian Wilmut, respectively [9–11], which paved way for targeting and altering genetic material and methods for growing human cells in the laboratory. These advances really launched stem cell research into the limelight, establishing the world's first human embryonic stem cell line which still exists today [12].

In the same year, John Gearhart (Johns Hopkins University) derived germ cells from cells in fetal gonadal tissue (primordial germ cells). Pluripotent stem cell “lines” were developed from both sources. The blastocysts used for human stem cell research typically come from in vitro fertilization (IVF) procedures. Since this discovery, a plethora of evidence has emerged to suggest that these embryonic stem cells are capable of becoming almost any of the specialized cells in the body and therefore have the potential to generate replacement cells for a broad array of tissues and organs such as the heart [13–15], liver [16,17], pancreas [18,19], and nervous system [20–22].

Progress in stem cell research is now astounding, with over 21,193 research papers on embryonic, iPS cells and adult stem cells being published globally in the year 2012 (Source:

Stem Cell Research: Trends and perspectives on the evolving international landscape. 2013 Elsevier B.V). Embryonic stem cells are still in its infancy in clinics with only 20 reported clinical trials till now; however, adult stem cells are already being used in treatments for over 4,000 clinical trials till date for a number of conditions including spinal cord injury, liver

cirrhosis, neurodegenerative diseases, leukemia, cardiac problems, and so on (results from A service of the U.S. National Institutes of Health: clinicaltrials.gov).

---

## Timeline of Stem Cell Research

1956	First successful bone marrow transplant between a related donor and recipient is performed by Dr E Donnal Thomas in New York. The patient, who has leukemia, is given radiotherapy and then treated with healthy bone marrow from an identical twin [7].
1958	Human histocompatibility antigens – Dausset discovers the first human leukocyte antigen [23].
1961	James Till and Ernest McCulloch first published evidence of the existence of stem cells in mouse bone marrow, a population of clonogenic bone marrow (BM) cells was found to generate myeloerythroid colonies in the spleens of lethally irradiated hosts [24].
1968	First bone marrow transplant for noncancer treatment. Dr Robert Good uses a bone marrow transplant to treat an 8-year-old boy with severe combined immunodeficiency syndrome (SCID). The donor is an HLA-matched sister ( <a href="http://www.fhrc.org/en/treatment/long-term-follow-up/FAQs/transplantation.html">http://www.fhrc.org/en/treatment/long-term-follow-up/FAQs/transplantation.html</a> ).
1970	Friedenstein and colleagues were the first to report that the rodent bone marrow had fibroblastoid cells, capable of forming colonies on plastic, which was later called a “mesenchymal stem cell” or MSC [25].
1973	First bone marrow transplant between unrelated patients. A 5-year-old SCID patient in New York treated with multiple infusions of bone marrow from a donor in Denmark ( <a href="http://www.fhrc.org/en/treatment/long-term-followup/FAQs/transplantation.html">http://www.fhrc.org/en/treatment/long-term-followup/FAQs/transplantation.html</a> ).
1978	The first IVF baby is born in England [26]. Blood stem cells are discovered in human umbilical cord blood [27].
1981	Mouse embryonic stem cells are derived for the first time from the inner cell mass of a mouse blastocyst and grown in vitro [9,10].
1984–1988	Isolated pluripotent cell line of human testicular teratocarcinoma [28], a first example of clonal human embryonal carcinoma cells. When exposed to retinoic acid, these cells differentiate into neuron-like cells and other cell types [29, 30].
1987	National Marrow Donor Program (NMDP) and its Be The Match Registry initiated [31].
1989	Preimplantation genetic diagnosis (PGD) is developed – a method where a single stem cell can be removed from an IVF embryo and tested for inherited diseases. A clonal line of human embryonal carcinoma cells is derived that yields tissues from all three primary germ layers. They have limited replicative and differentiative capacity [32].
1990	Dr Thomas receives the Nobel Prize in Physiology or Medicine for his pioneering work on bone marrow transplants ( <a href="http://www.nobelprize.org/nobel_prizes/medicine/laureates/1990/">http://www.nobelprize.org/nobel_prizes/medicine/laureates/1990/</a> ).
1992	The first direct evidence of nervous system stem cells came from the identification and isolation of rat neural crest stem cells, clonogenic precursors that give rise to all known neural crest cell types, while self-renewing the neural crest progenitors [33].
1995	Scientists at the University of Wisconsin derive the first embryonic stem cells from nonhuman primates. These cells were reported pluripotent [34].
1996	The first organism ever to be cloned from adult cells is Dolly [11].
1997	Leukemia is shown to originate from a hematopoietic stem cell, the first direct evidence for cancer stem cells [35].
1998	Scientists at the University of Wisconsin, led by James Thompson, isolate and grow the first stem cells from human embryos. The embryos used in these studies were created by IVF [12]. John Gearhart at Johns Hopkins University derived pluripotent germ cells from cells in fetal gonadal tissue (primordial germ cells) [36].

(continued)

---

2000	Scientists derive human ES cells from the inner cell mass of blastocysts. They proliferate in vitro for a long time and form all three germ layers and teratomas when injected into immunodeficient mice [37]. Retinal stem cells (RSCs) isolated from the pigmented ciliary epithelium (CE) of the mouse and differentiate into retinal-specific cell types, including rod photoreceptors, bipolar neurons, and Müller glia [38].
2001	US president George W. Bush prohibits federal funding of research on human embryonic stem cells. The president claims that more than 60 stem cell lines are available for funding ( <a href="http://georgewbushwhitehouse.archives.gov/news/releases/2001/08/20010809-2.html">http://georgewbushwhitehouse.archives.gov/news/releases/2001/08/20010809-2.html</a> ).
2003	Rare human breast cancer stem cells were identified and isolated [39]. Cancer stem cells isolated in human brain tumors [40].
2004	California becomes the first state in the USA to provide its own fund for embryonic stem cell research ( <a href="http://www.cirm.ca.gov/pdf/prop71.pdf">http://www.cirm.ca.gov/pdf/prop71.pdf</a> ).
2005	George W. Bush's restrictions on embryonic stem cell research are loosened ( <a href="http://query.nytimes.com/gst/fullpage.html?res=9A01E0DE113FF93AA15754C0A9639C8B63&amp;penalty-\@Msec=health">http://query.nytimes.com/gst/fullpage.html?res=9A01E0DE113FF93AA15754C0A9639C8B63&amp;penalty-\@Msec=health</a> ). Ernest McCulloch and James Till won the prestigious Albert Lasker Basic Medical Research Award, for first setting stage for all current research on adult and embryonic stem cells ( <a href="http://laskerfoundation.org/awards/2005_b_description.htm">http://laskerfoundation.org/awards/2005_b_description.htm</a> ).
2006	Induced pluripotent stem cells from mouse fibroblast cells by defined factors were generated [41].
2007	Evans shares the Nobel prize for medicine with Mario Capecchi and Oliver Smithies for their work on genetics and embryonic stem cells ( <a href="http://www.nobelprize.org/nobel_prizes/medicine/laureates/2007/">http://www.nobelprize.org/nobel_prizes/medicine/laureates/2007/</a> ). Induced pluripotent stem cells from adult fibroblast cells identified [42,43]. Researchers at Wake Forest University and Harvard University report that stem cells drawn from amniotic fluid donated by pregnant women hold much the same promise as embryonic stem cells [44].
2008	Robert Lanza and colleagues at Advanced Cell Technology create the first human embryonic stem cells lines created without destruction of the embryo [45]. First trachea transplant using woman's own stem cells [46].
2009	President Barack Obama lifts 2001 restrictions on federal funding for human embryonic stem cell research ( <a href="http://www.gpo.gov/fdsys/pkg/FR-2009-03-11/pdf/E9-5441.pdf">http://www.gpo.gov/fdsys/pkg/FR-2009-03-11/pdf/E9-5441.pdf</a> ).
2010	First clinical trial of human embryonic-derived stem cells for treatment of spinal cord injury [47].
2011	World's first stem cell-derived synthetic windpipe transplant ( <a href="http://www.newscientist.com/article/dn20671-man-receives-worlds-first-synthetic-windpipe.html#.UzIZGqiSxaY">http://www.newscientist.com/article/dn20671-man-receives-worlds-first-synthetic-windpipe.html#.UzIZGqiSxaY</a> ).
2012	Yamanaka wins a Nobel prize for creating induced pluripotent stem cells, which he shares with John Gurdon of the University of Cambridge ( <a href="http://www.nobelprize.org/nobel_prizes/medicine/laureates/2012/">http://www.nobelprize.org/nobel_prizes/medicine/laureates/2012/</a> ). Blindness eased by historic stem cell treatment [48].
2013	Scientists generate pluripotent stem cells derived from cloned human embryos. Reprogramming human skin cells, using a cloning technique called "somatic cell nuclear transfer" (SCNT) ( <a href="http://www.nature.com/news/human-stem-cells-created-by-cloning-1.12983">http://www.nature.com/news/human-stem-cells-created-by-cloning-1.12983</a> ).
2014	Charles Vacanti of Harvard Medical School together with Haruko Obokata at the Riken Center for Developmental Biology in Kobe, Japan, and colleagues announced a revolutionary discovery that any cell can potentially be reprogrammed to a pre-embryonic state using a simple, 30-min technique ( <a href="http://www.newscientist.com/article/mg22129542.500-stem-cell-power-unleashed-after-30-min-dip-in-acid.html#.Uzi-p6iSxaY">http://www.newscientist.com/article/mg22129542.500-stem-cell-power-unleashed-after-30-min-dip-in-acid.html#.Uzi-p6iSxaY</a> ). Masayo Takahashi at the same Riken Center is due to select patients for what promises to be the world's first trial of a therapy based on induced pluripotent stem cells, to treat a form of age-related blindness [49].

---

---

## Stem Cells and Its Promises

Despite the biomedical research advances of the last 50 years, much is still left to be discovered in human biology and millions of people still suffer from devastating diseases. Stem cell research started in the mid-1800s, and it is viewed from the researcher's point of view that stem cells are the key to understand the biology of various diseases and can lead to treatment and cures, and ultimately saves lives. Stem cells have the ability to literally develop into every cell of the body and thereby have the potential to replace damaged or diseased tissues and to treat disease. Stem cells are considered to have tremendous potential in repairing damaged organs, including the spinal cord, which normally does not undergo regeneration [50–52]. This ability to repair human tissue and to someday provide actual organ systems would provide hope to many with debilitating diseases [53–58].

The most obvious application of human stem cells and the one that receives the most attention are replacement therapies: to replace diseased or degenerating tissues or to replace cell populations, such as those of the hematopoietic system (e.g., blood), that have been destroyed by chemotherapy [59–63]. Stem cells could additionally provide an unlimited supply of specific cell types for transplantation. To date, stem cell-derived cardiomyocyte, neural precursors, and hematopoietic precursors have been transplanted into recipient animals [64–72]. Although the analyses of the long-term outcome of such experiments are limited, the findings suggest that the transplanted cells were able to function in the host animal. Stem cells have a high therapeutic value in the last few years to repair damaged spinal cords [73–76]; cure Crohn's disease and liver cirrhosis [77–84], Alzheimer's, and Parkinson's [85–91]; regrow arteries around a blockage [92–97]; regrow limbs [98–100]; replace failed kidneys and hearts [101–110]; cure diabetes by replacing nonfunctional cells in the pancreas [111–114]; restore vision and hearing [115–123]; and treat leukemia and lymphoma that are nonresponsive to normal therapy [124–129]. These are merely a few of the

potential applications of this phenomenal science. In fact most of the treatments listed above have already been studied, and with promising results. However, by latest, miraculous cures that supposedly occurred in faraway lands, the use of stem cells to treat certain degenerative diseases has not advanced beyond mice and needs extensive research.

Other applications of stem cells are in the study of development in both human and animal model systems. This approach includes the identification and isolation of novel precursor cells and of medically important genes. Such genes might encode proteins that have direct therapeutic applications, such as novel growth factors, or genes that would be important targets for drug development [130–135]. Human stem cells will also be valuable as a test system for evaluating the toxicity and efficacy of new medicines or chemicals. The wide ranges of cell types and tissues that may develop from stem cells represent a biological system that mimics many of the complex interactions of the cells and tissues of the body and, as such, provides an attractive and valuable screening tool. This type of assay could have wide applications in the pharmaceutical, chemical, cosmetics, and agrochemical industries. It has the potential to reduce the need for animal testing and to increase efficiency and safety and reduces the costs of developing safe and effective drugs and chemicals [136–140].

Hence, it is clear that stem cell technology continues to revolutionize modern biology and provide unique opportunities in understanding of both the mechanisms that control basic biological processes and in the treatment of diseases. Additional research will be necessary to apply the full therapeutic potential of this technology, but the resulting novel therapies and approaches should more than justify the effort.

---

## Conclusion

Stem cell research provides a useful tool for unraveling the molecular mechanisms that determine the differentiation fate of a pluripotent cell and for understanding the gene expression

properties and epigenetic modifications essential to maintain the pluripotent state. There are many ways in which human stem cells can be used in basic and translational research. However, there are a number of hurdles in the path of stem cell research that are preventing the routine application of the technology in regenerative medicine. This will only be overcome by continuous extensive research. Currently, stem cell research is nearing transplantation therapies with high efficiency whereby a specific cell population compromised by disease is replaced with new, functional cells. The greatest promise of stem cell research may lie in an area not yet imagined.

## References

1. Bruder SP, Fink DJ, Caplan AI (1994) Mesenchymal stem cells in bone development, bone repair, and skeletal regeneration therapy. *J Cell Biochem* 56(3):283–294
2. Kolb HJ, Holler E (1997) Hematopoietic transplantation: state of the art. *Stem Cells* 15(Suppl 1):151–157, discussion 158
3. Prockop DJ (1997) Marrow stromal cells as stem cells for nonhematopoietic tissues. *Science* 276:71–74
4. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R et al (1999) Multilineage potential of adult human mesenchymal stem cells. *Science* 284:143–147
5. Weissman IL (2000) Stem cells: units of development, units of regeneration, and units in evolution. *Cell* 100:157–168
6. Gilbert SF (2000) *Developmental biology*, 6th edn. Sinauer Associates, Sunderland
7. Thomas ED, Lochte HL Jr, Lu WC, Ferrebee J (1957) Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. *N Engl J Med* 257:491
8. Theresa H, McCarthy PL Jr, Hassebroek A, Bredeson C, Gajewski JL et al (2013) Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. *J Clin Oncol* 31(19):2437–2449
9. Evans MJ, Kaufman MH (1981) Establishment in culture of pluripotential cells from mouse embryos. *Nature* 292:154–156
10. Martin GR (1981) Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. *Proc Natl Acad Sci U S A* 78:7634–7638
11. Wilmut I, Schnieke AE, McWhir J et al (1997) Viable offspring derived from fetal adult mammalian cells. *Nature* 385:810
12. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM (1998) Embryonic stem cell lines derived from human blastocysts. *Science* 282:1145–1147
13. Leor J, Gerecht S, Cohen S, Miller L, Holbova R et al (2007) Human embryonic stem cell transplantation to repair the infarcted myocardium. *Heart* 93(10):1278–1284
14. Ardehali R, Ali SR, Inlay MA, Abilez OJ, Chen MQ et al (2013) Prospective isolation of human embryonic stem cell-derived cardiovascular progenitors that integrate into human fetal heart tissue. *Proc Natl Acad Sci U S A* 110(9):3405–3410
15. Karakikes I, Senyei GD, Hansen J, Kong CW, Azeloglu EU et al (2014) Small molecule-mediated directed differentiation of human embryonic stem cells toward ventricular cardiomyocytes. *Stem Cells Transl Med* 3(1):18–31
16. Hay DC, Zhao D, Ross A, Mandalam R, Lebkowski J et al (2007) Direct differentiation of human embryonic stem cells to hepatocyte-like cells exhibiting functional activities. *Cloning Stem Cells* 9(1):51–62
17. Pal R, Mamidi MK, Das AK, Gupta PK, Bhonde R (2012) A simple and economical route to generate functional hepatocyte-like cells from hESCs and their application in evaluating alcohol induced liver damage. *J Cell Biochem* 113(1):19–30
18. Shim JH, Kim SE, Woo DH, Kim SK, Oh CH et al (2007) Directed differentiation of human embryonic stem cells towards a pancreatic cell fate. *Diabetologia* 50(6):1228–1238
19. Bose B, Shenoy SP, Konda S, Wangikar P (2012) Human embryonic stem cell differentiation into insulin secreting  $\beta$ -cells for diabetes. *Cell Biol Int* 36(11):1013–1020
20. Zhang SC, Wernig M, Duncan ID, Brüstle O, Thomson JA (2001) In vitro differentiation of transplantable neural precursors from human embryonic stem cells. *Nat Biotechnol* 19(12):1129–1133
21. Kriks S, Shim JW, Piao J, Ganat YM, Wakeman DR et al (2011) Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. *Nature* 480(7378):547–551
22. Maroof AM, Keros S, Tyson JA, Ying SW, Ganat YM et al (2013) Directed differentiation and functional maturation of cortical interneurons from human embryonic stem cells. *Cell Stem Cell* 12(5):559–572
23. Dausset J (1958) Iso-leuco-anticorps. *Acta Haematol* 20:156
24. Till J, McCulloch E (1961) A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. *Radiat Res* 14:213–224
25. Friedenstein AJ, Chailakhjan RK, Lalykina KS (1970) The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. *Cell Tissue Kinet* 3(4):393–403

26. Trounson AO, Gardner DK, Baker G, Barnes FL, Bongso A et al (2000) Handbook of in vitro fertilization. CRC Press, Boca Raton/London/New York/Washington, DC
27. Prindull G, Prindull B, Meulen N (1978) Haematopoietic stem cells (CFUc) in human cord blood. *Acta Paediatr Scand* 67(4):413–416
28. Andrews PW, Damjanov I, Simon D, Banting GS, Carlin C et al (1984) Pluripotent embryonal carcinoma clones derived from the human teratocarcinoma cell line Tera-2. Differentiation in vivo and in vitro. *Lab Invest* 50(2):147–162
29. Thompson S, Stern PL, Webb M, Walsh FS, Engstrom W et al (1984) Cloned human teratoma cells differentiate into neuron-like cells and other cell types in retinoic acid. *J Cell Sci* 72:37–64
30. Andrews PW (1988) Human teratocarcinomas. *Biochim Biophys Acta* 948:17–36
31. NIH MedlinePlus Magazine. Bone Marrow Transplants: The National Marrow Donor Program and Be The Match Registry. Summer 2011. 6(2):17
32. Handyside AH, Pattinson JK, Penketh RJ, Delhanty JD, Winston RM et al (1989) Biopsy of human preimplantation embryos and sexing by DNA amplification. *Lancet* 1(8634):347–349
33. Stemple DL, Anderson DJ (1992) Isolation of a stem cell for neurons and glia from the mammalian neural crest. *Cell* 71(6):973–985
34. Thomson JA, Kalishman J, Golos TG, Durning M, Harris CP et al (1995) Isolation of a primate embryonic stem cell line. *Proc Natl Acad Sci USA* 92:7844–7848
35. Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. *Nat Med* 3:730–737
36. Shambloott MJ, Axelman J, Wang S, Bugg EM, Littlefield J et al (1998) Derivation of pluripotent stem cells from cultured human primordial germ cells. *Proc Natl Acad Sci U S A* 95(23):13726–13731
37. Reubinoff BE, Pera MF, Fong CY, Trounson A, Bongso A (2000) Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro. *Nat Biotechnol* 18(4):399–404
38. Tropepe V, Coles BLK, Chiasson BJ, Horsford DJ, Elia AJ et al (2000) Retinal stem cells in the adult mammalian eye. *Science* 287:2032–2203
39. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. *Proc Natl Acad Sci U S A* 100:3983–3988
40. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB (2003) Identification of a cancer stem cell in human brain tumors. *Cancer Res* 63:5821–5828
41. Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 126:663–676
42. Yu J, Vodyanik MA et al (2007) Induced pluripotent stem cell lines derived from human somatic cells. *Science* 318(5858):1917–1920
43. Takahashi K et al (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 131(5):861–872
44. De Coppi P, Jr Bartsch G, Minhaj Siddiqui M, Tao X, Santos CC et al (2007) Isolation of amniotic stem cell lines with potential for therapy. *Nat Biotechnol* 25:100–106
45. Advanced cell technology. Human embryonic stem cells lines created without destruction of the embryos. *ScienceDaily* 2008
46. Macchiarini P, Jungebluth P, Go T, Asnaghi MA, Rees LE et al (2008) Clinical transplantation of a tissue-engineered airway. *Lancet* 372(9655):2023–2030
47. Bretzner F, Gilbert F, Baylis F, Brownstone RM (2011) Target populations for first-in-human embryonic stem cell research in spinal cord injury. *Cell Stem Cell* 8(5):468–475
48. Schwartz SD, Hubschman J-P, Heilwell G, Franco-Cardenas V et al (2012) Embryonic stem cell trials for macular degeneration: a preliminary report. *Lancet* 379(9817):713–720
49. Kamao H, Mandai M, Okamoto S, Sakai N, Suga A et al (2014) Characterization of human induced pluripotent stem cell-derived retinal pigment epithelium cell sheets aiming for clinical application. *Stem Cell Rep* 2:1–14
50. Yoon SH, Shim YS, Park YH, Chung JK, Nam JH et al (2007) Complete spinal cord injury treatment using autologous bone marrow cell transplantation and bone marrow stimulation with granulocyte macrophage-colony stimulating factor: Phase I/II clinical trial. *Stem Cells* 25(8):2066–2073
51. Chernykh ER, Stupak VV, Muradov GM, Sizikov MY, Shevela EY et al (2007) Application of autologous bone marrow stem cells in the therapy of spinal cord injury patients. *Bull Exp Biol Med* 143(4):543–547
52. Cristante AF, Barros-Filho TE, Tatsui N, Mendrone A, Caldas JG et al (2009) Stem cells in the treatment of chronic spinal cord injury: evaluation of somatosensitive evoked potentials in 39 patients. *Spinal Cord* 47(10):733–738
53. Vieira NM, Brandalise V, Zucconi E, Jazedje T, Secco M et al (2008) Human multipotent adipose-derived stem cells restore dystrophin expression of Duchenne skeletal-muscle cells in vitro. *Biol Cell* 100(4):231–241
54. Bahat-Stroomza M, Barhum Y, Levy YS, Karpov O, Bulvik S et al (2009) Induction of adult human bone marrow mesenchymal stromal cells into functional astrocyte-like cells: potential for restorative treatment in Parkinson's disease. *J Mol Neurosci* 39(1–2):199–210
55. González MA, Gonzalez-Rey E, Rico L, Büscher D, Delgado M (2009) Treatment of experimental

- arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. *Arthritis Rheum* 60(4):1006–1019
56. Connick P, Kolappan M, Crawley C, Webber DJ, Patani R et al (2012) Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. *Lancet Neurol* 11(2):150–156
  57. Glass JD, Boulis NM, Johe K, Rutkove SB, Federici T et al (2012) Lumbar intraspinal injection of neural stem cells in patients with amyotrophic lateral sclerosis: results of a phase I trial in 12 patients. *Stem Cells* 30(6):1144–1151
  58. Paracchini V, Carbone A, Colombo F, Castellani S, Mazzucchelli S et al (2012) Amniotic mesenchymal stem cells: a new source for hepatocyte-like cells and induction of CFTR expression by coculture with cystic fibrosis airway epithelial cells. *J Biomed Biotechnol* 2012:575471
  59. Intragumtornchai T, Jootar S, Unganon A, Swadikul D, Udomprasertgul V (1999) Quality of life in Thai patients after bone marrow and peripheral blood stem cell transplantation: a comparison study with patients treated with conventional chemotherapy. *Int J Hematol* 70(3):181–189
  60. Michallet M, Philip T, Philip I, Godinot H, Sebban C et al (2000) Transplantation with selected autologous peripheral blood CD34 + Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitution. *Exp Hematol* 28(7):858–870
  61. Müller AM, Kohrt HE, Cha S, Laport G, Klein J et al (2012) Long-term outcome of patients with metastatic breast cancer treated with high dose chemotherapy and transplantation of purified autologous hematopoietic stem cells. *Biol Blood Marrow Transplant* 18(1):125–133
  62. Wallet HL, Sobh M, Morisset S, Robin M, Fegueux N et al (2013) Double umbilical cord blood transplantation for hematological malignancies: a long-term analysis from the SFGM-TC registry. *Exp Hematol* 41(11):924–933
  63. Fouillard L, Francois S, Bouchet S, Bensidhoum M, Elm'selmi A, Chapel A (2014) Innovative cell therapy in the treatment of serious adverse events related to both chemo-radiotherapy protocol and acute myeloid leukemia syndrome: the infusion of mesenchymal stem cells post-treatment reduces hematopoietic toxicity and promotes hematopoietic reconstitution. *Curr Pharm Biotechnol* 14(9):842–848
  64. Smits AM, van Laake LW, den Ouden K, Schreurs C, Szuhai K et al (2009) Human cardiomyocyte progenitor cell transplantation preserves long-term function of the infarcted mouse myocardium. *Cardiovasc Res* 83(3):527–535
  65. Okura H, Matsuyama A, Lee CM, Saga A, Kakuta-Yamamoto A et al (2010) Cardiomyoblast-like cells differentiated from human adipose tissue-derived mesenchymal stem cells improve left ventricular dysfunction and survival in a rat myocardial infarction model. *Tissue Eng Part C Methods* 16(3):417–425
  66. Kawamura M, Miyagawa S, Fukushima S, Saito A, Miki K et al (2013) Enhanced survival of transplanted human induced pluripotent stem cell-derived cardiomyocytes by the combination of cell sheets with the pedicled omental flap technique in a porcine heart. *Circulation* 128(11 Suppl 1):S87–S94
  67. Zhilai Z, Hui Z, Yin Hai C, Zhong C, Shaoxiong M et al (2011) Combination of NEP 1-40 infusion and bone marrow-derived neurospheres transplantation inhibit glial scar formation and promote functional recovery after rat spinal cord injury. *Neurol India* 59(4):579–585
  68. Drury-Stewart D, Song M, Mohamad O, Guo Y, Gu X et al (2013) Highly efficient differentiation of neural precursors from human embryonic stem cells and benefits of transplantation after ischemic stroke in mice. *Stem Cell Res Ther* 4(4):93
  69. Fujiwara N, Shimizu J, Takai K, Arimitsu N, Saito A et al (2013) Restoration of spatial memory dysfunction of human APP transgenic mice by transplantation of neuronal precursor derived from human iPS cells. *Neurosci Lett pii*(13):00947-6
  70. Benjamin BP, Galy A, Kyoizumi S, Namikawa R, Scarborough J et al (1994) Engraftment of human hematopoietic precursor cells with secondary transfer potential in SCID-hu mice. *Blood* 84(8):2497–2505
  71. Liu Y, Yi L, Zhang X, Gao L, Zhang C et al (2011) Cotransplantation of human umbilical cord blood derived stromal cells enhances hematopoietic reconstitution and engraftment in irradiated BABL/c mice. *Cancer Biol Ther* 11(1):84–94
  72. Shi Q, Kuether EL, Chen Y, Schroeder JA, Fahs SA et al (2014) Platelet gene therapy corrects the hemophilic phenotype in immunocompromised hemophilia A mice transplanted with genetically manipulated human cord blood stem cells. *Blood* 123(3):395–403
  73. Mazzini L, Ferrero I, Luparello V, Rustichelli D, Gunetti M et al (2010) Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: a Phase I clinical trial. *Exp Neurol* 223(1):229–237
  74. Karamouzian S, Nematollahi-Mahani SN, Nakhaee N, Eskandary H (2012) Clinical safety and primary efficacy of bone marrow mesenchymal cell transplantation in sub acute spinal cord injured patients. *Clin Neurol Neurosurg* 114(7):935–939
  75. Liu J, Chen J, Liu B, Yang C, Xie D et al (2013) Acellular spinal cord scaffold seeded with mesenchymal stem cells promotes long-distance axon regeneration and functional recovery in spinal cord injured rats. *J Neurol Sci* 325(1–2):127–136
  76. Amr SM, Gouda A, Koptan WT, Galal AA, Abdel-Fattah DS et al (2014) Bridging defects in chronic spinal cord injury using peripheral nerve grafts combined with a chitosan-laminin scaffold and enhancing regeneration through them by co-transplantation

- with bone-marrow-derived mesenchymal stem cells: Case series of 14 patients. *J Spinal Cord Med* 37(1):54–71
77. Goldman O, Han S, Sourrisseau M, Dziedzic N, Hamou W et al (2013) KDR identifies a conserved human and murine hepatic progenitor and instructs early liver development. *Cell Stem Cell* 12(6):748
  78. Jang YO, Kim YJ, Baik SK, Kim MY, Eom YW et al (2014) Histological improvement following administration of autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: a pilot study. *Liver Int* 34(1):33–41
  79. Liao X, AnCheng JY, Zhou QJ, Liao C (2013) Therapeutic effect of autologous bone marrow-derived liver stem cells transplantation in hepatitis B virus-induced liver cirrhosis. *Hepatogastroenterology* 60(123):406–409
  80. Hong J, Jin H, Han J, Hu H, Liu J et al (2014) Infusion of human umbilical cord-derived mesenchymal stem cells effectively relieves liver cirrhosis in DEN-induced rats. *Mol Med Rep* 9(4):1103–1111
  81. de la Portilla F, Alba F, García-Olmo D, Herrerías JM, González FX, Galindo A (2013) Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn's disease: results from a multicenter phase I/IIa clinical trial. *Int J Colorectal Dis* 28(3):313–323
  82. Ciccocioppo R, Bernardo ME, Sgarella A, Maccario R, Avanzini MA et al (2011) Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. *Gut* 60(6):788–798
  83. Burt RK, Craig RM, Milanetti F, Quigley K, Gozdziaik P et al (2010) Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up. *Blood* 116(26):6123–6132
  84. González MA, Gonzalez-Rey E, Rico L, Büscher D, Delgado M (2000) Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. *Gastroenterology* 136(3):978–989
  85. Doi D, Samata B, Katsukawa M, Kikuchi T, Morizane A, Ono Y et al (2014) Isolation of human induced pluripotent stem cell-derived dopaminergic progenitors by cell sorting for successful transplantation. *Stem Cells Transl Med* 2(3):337–50
  86. Battista D, Ganat Y, El Maarouf A, Studer L, Rutishauser U (2014) Enhancement of polysialic acid expression improves function of embryonic stem-derived dopamine neuron grafts in Parkinsonian mice. *Stem Cells Transl Med* 3(1):108–113
  87. Yan M, Sun M, Zhou Y, Wang W, He Z et al (2013) Conversion of human umbilical cord mesenchymal stem cells in Wharton's jelly to dopamine neurons mediated by the Lmx1a and neurturin in vitro: potential therapeutic application for Parkinson's disease in a rhesus monkey model. *PLoS One* 8(5):e64000
  88. Sundberg M, Bogetofte H, Lawson T, Jansson J, Smith G, Astradsson A et al (2013) Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons. *Stem Cells* 31(8):1548–1562
  89. Bae JS, Jin HK, Lee JK, Richardson JC, Carter JE (2013) Bone marrow-derived mesenchymal stem cells contribute to the reduction of amyloid- $\beta$  deposits and the improvement of synaptic transmission in a mouse model of pre dementia Alzheimer's disease. *Curr Alzheimer Res* 10(5):524–531
  90. Lee HJ, Lee JK, Lee H, Shin JW, Carter JE et al (2010) The therapeutic potential of human umbilical cord blood-derived mesenchymal stem cells in Alzheimer's disease. *Neurosci Lett* 481(1):30–35
  91. Wicklund L, Leão RN, Strömberg AM, Mousavi M, Hovatta O et al (2010) B-amyloid 1-42 oligomers impair function of human embryonic stem cell-derived forebrain cholinergic neurons. *PLoS One* 5(12):e15600
  92. Mutirangura P, Ruangsetakit C, Wongwanit C, Chinsakchai K, Porat Y et al (2009) Enhancing limb salvage by non-mobilized peripheral blood angiogenic cell precursors therapy in patients with critical limb ischemia. *J Med Assoc Thai* 92(3):320–327
  93. Kim H, Cho HJ, Kim SW, Liu B, Choi YJ et al (2010) CD31+ cells represent highly angiogenic and vasculogenic cells in bone marrow: novel role of nonendothelial CD31+ cells in neovascularization and their therapeutic effects on ischemic vascular disease. *Circ Res* 107(5):602–614
  94. Rahnamai-Azar A, D'Ippolito G, Gomez LA, Reiner T, Vazquez-Padron RI et al (2011) Human marrow-isolated adult multilineage-inducible (MIAMI) cells protect against peripheral vascular ischemia in a mouse model. *Cytotherapy* 13(2):179–192
  95. Padfield GJ, Tura-Ceide O, Freyer E, Barclay GR, Turner M et al (2013) Endothelial progenitor cells, atheroma burden and clinical outcome in patients with coronary artery disease. *Heart* 99(11):791–798
  96. Katare R, Riu F, Rowlinson J, Lewis A, Holden R et al (2013) Perivascular delivery of encapsulated mesenchymal stem cells improves post ischemic angiogenesis via paracrine activation of VEGF-A. *Arterioscler Thromb Vasc Biol* 33(8):1872–1880
  97. Katare R, Stroemer P, Hicks C, Stevanato L, Patel S et al (2014) Clinical-grade human neural stem cells promote reparative neovascularization in mouse models of hindlimb ischemia. *Arterioscler Thromb Vasc Biol* 34(2):408–418
  98. Rinkevich Y, Lindau P, Ueno H, Longaker MT, Weissman IL (2011) Germ-layer and lineage-restricted stem/progenitors regenerate the mouse digit tip. *Nature* 476(7361):409–413
  99. Lehoczy JA, Robert B, Tabin CJ (2011) Mouse digit tip regeneration is mediated by fate-restricted progenitor cells. *Proc Natl Acad Sci U S A* 108(51):20609–20614

100. Fernando WA, Leininger E, Simkin J, Li N, Malcom CA et al (2011) Wound healing and blastema formation in regenerating digit tips of adult mice. *Dev Biol* 350(2):301–310
101. Wagner L, Lengyel L, Mikala G, Reményi P, Piros L et al (2013) Successful treatment of renal failure caused by multiple myeloma with HLA-identical living kidney and bone marrow transplantation: a case report. *Transplant Proc* 45(10):3705–3707
102. Narayanan K, Schumacher KM, Tasnim F, Kandasamy K, Schumacher A et al (2013) Human embryonic stem cells differentiate into functional renal proximal tubular-like cells. *Kidney Int* 83: 593–603
103. Harari-Steinberg O, Metsuyanım S, Omer D, Gnatek Y, Gershon R et al (2013) Identification of human nephron progenitors capable of generation of kidney structures and functional repair of chronic renal disease. *EMBO Mol Med* 5(10):1556–1568
104. Perico N, Casiraghi F, Gotti E, Inrona M, Todeschini M et al (2013) Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation. *Transpl Int* 26(9):867–878
105. Bukulmez H, Bilgin A, Caplan AI, Jones O (2014) Prevention of late stage renal failure in BXSB SLE mouse model with human bone marrow derived mesenchymal stem cell treatment. *Arthritis Rheumatol* 66(Suppl 11):S149
106. Leistner DM, Fischer-Rasokat U, Honold J, Seeger FH, Schächinger V et al (2011) Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI): final 5-year results suggest long-term safety and efficacy. *Clin Res Cardiol* 100(10):925–934
107. Bolli R, Chugh AR, D'Amario D, Loughran JH, Stoddard MF et al (2011) Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. *Lancet* 378(9806):1847–1857
108. Jianqin Y, Boyle A, Shih H, Sievers RE, Zhang Y et al (2012) Sca-1<sup>+</sup> cardiosphere-derived cells are enriched for Isl1-expressing cardiac precursors and improve cardiac function after myocardial injury. *PLoS One* 7(1):e30329
109. Martinez EC, Vu DT, Wang J, Lilyanna S, Ling LH et al (2013) Grafts enriched with sub amnion-cord-lining mesenchymal stem cell angiogenic spheroids induce post-ischemic myocardial revascularization and preserve cardiac function in failing rat hearts. *Stem Cells Dev* 22(23):3087–3099
110. Heldman AW, DiFede DL, Fishman JE, Zambrano JP, Trachtenberg BH (2014) Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. *JAMA* 311(1):62–73
111. Rezanıa A, Bruin JE, Riedel MJ, Mojibian M, Asadi A et al (2012) Maturation of human embryonic stem cell-derived pancreatic progenitors into functional islets capable of treating pre-existing diabetes in mice. *Diabetes* 61(8):2016–2029
112. Zhao Y, Jiang Z, Zhao T, Ye M, Hu C et al (2012) Reversal of type 1 diabetes via islet  $\beta$  cell regeneration following immune modulation by cord blood-derived multipotent stem cells. *BMC Med* 10:3
113. Zhao Y, Jiang Z, Zhao T, Ye M et al (2013) Targeting insulin resistance in type 2 diabetes via immune modulation of cord blood-derived multipotent stem cells (CB-SCs) in stem cell educator therapy: phase I/II clinical trial. *BMC Med* 11
114. Dave SD, Trivedi HL, Chooramani SG, Chandra T (2013) Management of type 1 diabetes mellitus using in vitro autologous adipose tissue transdifferentiated insulin-making cells. *BMJ Case Rep*
115. Siqueira RC, Messias A, Voltarelli JC, Scott IU, Jorge R (2011) Intravitreal injection of autologous bone marrow-derived mononuclear cells for hereditary retinal dystrophy: a phase I trial. *Retina* 31(6):1207–1214
116. Marchini G, Pedrotti E, Pedrotti M, Barbaro V, Di Iorio E, Ferrari S et al (2012) Long-term effectiveness of autologous cultured limbal stem cell grafts in patients with limbal stem cell deficiency due to chemical burns. *Clin Experiment Ophthalmol* 40(3):255–267
117. Basu S, Ali H, Sangwan VS (2012) Clinical outcomes of repeat autologous cultivated limbal epithelial transplantation for ocular surface burns. *Am J Ophthalmol* 153(4):643–650
118. Hambright D, Park KY, Brooks M, McKay R, Swaroop A, Nasonkin IO (2012) Long-term survival and differentiation of retinal neurons derived from human embryonic stem cell lines in un-immunosuppressed mouse retina. *Mol Vis* 18: 920–936
119. Li T, Lewallen M, Chen S, Yu W, Zhang N, Xie T (2013) Multipotent stem cells isolated from the adult mouse retina are capable of producing functional photoreceptor cells. *Cell Res* 23(6):788–802
120. Kamao H, Mandai M, Okamoto S, Sakai N, Suga A et al (2014) Characterization of human induced pluripotent stem cell-derived retinal pigment epithelium cell sheets aiming for clinical application. *Stem Cell Rep* 2(2):205–218
121. Oshima K, Shin K, Diensthuber M, Peng AW et al (2010) Mechanosensitive hair cell-like cells from embryonic and induced pluripotent stem cells. *Cell* 141(4):704–716.
122. Koehler KR, Mikosz AM, Molosh AI, Patel D et al (2013) Generation of inner ear sensory epithelia from pluripotent stem cells in 3D culture. *Nature* 500(7461):217–221
123. Liu Z, Fang J, Dearman J, Zhang L, Zuo J (2014) In vivo generation of immature inner hair cells in neonatal mouse cochleae by ectopic atoh1 expression. *PLoS One* 9(2):e89377
124. Kobos R, Steiner PG, Kernan NA, Prockop SE, Scaradavou A et al (2012) Allogeneic hematopoietic stem cell transplantation for pediatric patients with treatment-related myelodysplastic syndrome or acute myelogenous leukemia. *Biol Blood Marrow Transplant* 18(3):473–480

125. Hale GA, Shrestha S, Le-Rademacher J, Burns LJ, Gibson J et al (2012) Alternate donor hematopoietic cell transplantation (HCT) in non Hodgkin lymphoma using lower intensity conditioning: a report from the CIBMTR. *Biol Blood Marrow Transplant* 18(7):1036–1043
126. Bhatnagar B, Rapoport AP, Fang HB, Ilyas C, Marangoz D et al (2014) Single center experience with total body irradiation and melphalan (TBI-MEL) myeloablative conditioning regimen for allogeneic stem cell transplantation (SCT) in patients with refractory hematologic malignancies. *Ann Hematol* 93(4):653–660
127. Han Q, Sun M, Wu L, Chen J, Wang W et al (2014) Primary distal femur T-cell lymphoma after allogeneic haematopoietic stem cell transplantation for chronic myeloid leukaemia: a rare case report and literature review. *J Int Med Res* 42(2): 598–605
128. Cohen JB, Geyer SM, Lozanski G, Zhao W, Heerema NA et al (2014) Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival. *Cancer* 120(11):1677–1685
129. McClune BL, Ahn KW, Wang HL, Antin JH, Artz AS et al (2014) Allotransplantation for patients age 40 years and greater with non-Hodgkin Lymphoma (NHL): encouraging progression-free survival. *Biol Blood Marrow Transplant pii:S1083–S8791*
130. Lee G, Papapetrou EP, Kim H, Chambers SM et al (2009) Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. *Nature* 461:402–406
131. Itzhaki I, Maizels L, Huber I, Zwi-Dantsis L, Caspi O et al (2011) Modelling the long QT syndrome with induced pluripotent stem cells. *Nature* 471:225–229
132. Boone N, Bergon A, Loriod B, Devèze A, Nguyen C et al (2012) Genome-wide analysis of familial dysautonomia and kinetin target genes with patient olfactory ecto-mesenchymal stem cells. *Hum Mutat* 33(3):530–540
133. Robinton DA, Daley GQ (2012) The promise of induced pluripotent stem cells in research and therapy. *Nature* 481(7381):295–305
134. Xu XH, Zhong Z (2013) Disease modeling and drug screening for neurological diseases using human induced pluripotent stem cells. *Acta Pharmacol Sin* 34:755–764
135. Musunuru K, Domian IJ, Chien KR (2010) Stem cell models of cardiac development and disease. *Annu Rev Cell Dev Biol* 26:667–687
136. Zeng X, Chen J, Deng X, Liu Y, Rao MS et al (2006) An in vitro model of human dopaminergic neurons derived from embryonic stem cells: MPP + toxicity and GDNF neuroprotection. *Neuropsychopharmacology* 31:2708–2715
137. Wobus AM, Löser P (2011) Present state and future perspectives of using pluripotent stem cells in toxicology research. *Arch Toxicol* 85(2):79–117
138. Marx U, Walles H, Hoffmann S, Lindner G, Horland R et al (2012) ‘Human-on-a-chip’ developments: a translational cutting-edge alternative to systemic safety assessment and efficiency evaluation of substances in laboratory animals and man? *Altern Lab Anim* 40(5):235–257
139. Kostadinova R, Boess F, Applegate D, Suter L, Weiser T et al (2013) A long-term three dimensional liver co-culture system for improved prediction of clinically relevant drug-induced hepatotoxicity. *Toxicol Appl Pharmacol* 268(1):1–16
140. Sciancalepore AG, Sallustio F, Girardo S, Gioia Passione L, Camposeo A et al (2014) A bioartificial renal tubule device embedding human renal stem/progenitor cells. *PLoS One* 9(1):87496